Response to acetazolamide in a patient with tumoural calcinosis  by Landini-Enríquez, Venecia et al.
 5;3  5
D
S
U
Z
∗
E
z
L
R a  
c
R ien
T
T
m
d
a
i
(
l
r
t
c
o
s
p
a
t
t
t
c
o
1
e
r
j
u
h
c
points can lead to increased tubular phosphorus reabsorption,n e f r o l o g i a 2 0 1
ong Liu, Yanna Dou, Wenming Yuan, Zeyu Li,
ongxia Quan, Jing Xiao, Zhanzheng Zhao ∗
Nephrology Center of The First Afﬁliated Hospital of Zhengzhou
niversity, Zhengzhou University Institute of Nephrology,
hengzhou, Henan, China
Corresponding author.
-mail addresses: 13938525666@139.com,
haozhanzheng2014@126.com (Z. Zhao).
etters to the Editor - Case Report
esponse  to  acetazolamide  in 
alcinosis
espuesta  a  acetazolamida  en  pac
o the Editor,
umoural calcinosis (TC) is a rare disorder of phosphorus
etabolism, characterised by the formation of periarticular
eposits of calcium phosphate.1 The disease is the result of
 defect in renal phosphorus excretion, due to mutations
n the genes for ﬁbroblast growth factor 23 (FGF23), Klotho
KL), and N-acetylgalactosaminyltransferase-3 (GALNT3). The
oss of FGF23 function results in increased tubular phospho-
us reabsorption, and subsequent deposition in subcutaneous
isses.2
We  present the case of a 23-year-old man  with no signiﬁ-
ant past medical history, whose symptoms began at the age
f 18 years, with the appearance of a mass in the right dor-
al region, lateral buttock, and thigh. The patient reported a
rogressive increase in size of the mass, related with physical
ctivity, and pain in the affected limb as a functional limi-
ation. Six months before his admission to our hospital, the
umour had been excised, measuring 18 × 7 cm from the right
high, and 20 × 10 cm from the right buttock, with amorphous
haracteristics.
On admission, he had a solid painless mass in the area
f excision on the superﬁcial lateral right thigh, measuring
0 × 4 × 6 cm.  Laboratory analysis reported normal serum lev-
ls of calcium, phosphate, creatinine, albumin, and PTH. X-ray
evealed a multinodular calciﬁed mass around the right hip
oint.
Biopsy of the lesion reported amorphous calciﬁed nod-
les, some surrounded by a proliferation of macrophages and
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osteoclast-like giant cells, separated by dense ﬁbrous tissue,
consistent with TC (Fig. 1). He was followed up for 2 years
while receiving acetazolamide (August 2008 to October 2011)
and showed clinical improvement and cessation of growth of
the lesions. There were no reported acid–base disturbances
during treatment. A follow-up X-ray was taken 7 years after
starting treatment, with no increase in the size of the lesions
(Fig. 2).
The pathophysiology of TC is based on abnormal phospho-
rus metabolism.3 Serum phosphate concentration is regulated
by endocrine communication between bone, kidney, and
the intestine.4 The endocrine factors involved in phosphate
metabolism are 1,25-hydroxyvitamin D3, parathyroid hor-
mone (PTH) and FGF23. FGF23 and PTH act synergistically to
reduce the expression of the cotransporters NaPi-IIa and NaPi-
IIc in the brush border of the proximal renal tubule, increasing
renal phosphorus excretion.5
FGF 23 is a glycoprotein, formed by 251 amino acids, and
has an N-terminal and a C-terminal made of 71 amino acids.6
It promotes phosphorus excretion by reducing the expression
of NaP(i) cotransporters in the proximal tubular cell brush
border.3 For FGF23 to bind to its receptor, FGFR1c, Klotho is
essential to form a functional heterodimer.7 FGF23 is gly-
cosylated by GALNT3.8 Only the complete FGF23 protein is
biologically active. Therefore, an abnormality at any of thesega E, Chamizo-Aguilar K. Respuesta a acetazolamida en paciente
which is what happens in TC.3
The disease manifests as hyperphosphatemia and massive
calcium deposition in the subcutaneous tissue, which are the
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Fig. 1 – Histological sections of the lesions in the right buttock and thigh, in a 23-year-old patient. (a) Areas with a cystic
appearance with calcium deposits and epithelioid cells. (b) Presence of multinucleate giant cells.
Fig. 2 – Comparative radiographic imaging of a patient with TC after 7 years of acetazolamide treatment: (a) Start of
treatment (August 2008). (b) Follow-up (February 2015).
main causes of patient symptoms.3 This disease is more  fre-
quent in women and in patients of African origin, with initial
presentation in childhood or early adolescence.2
The treatment of TC can be divided into surgical
excision and medical treatment. Surgical excision of the
lesion is a well-documented treatment, but recurrence
is common. Furthermore, this patient had shown recur-
rence after surgical excision, probably due to the tumour
being poorly-circumscribed.9 Medical treatment is preferable
because of the metabolic nature of the disease. Described
treatments include dietary phosphate restriction, antacids,
phosphaturic drugs, and phosphate binders. However, the
most effective demonstrated treatment is the combina-
tion of surgical excision with phosphate restriction and
acetazolamide.10Previous studies have demonstrated positive results with
the use of acetazolamide as a phosphaturic treatment for
TC, causing mild metabolic acidosis in these patients as
an adverse effect. Acetazolamide, a sulphonamide-derivative,
acts as a carbonic anhydrase inhibitor in the apical and
basolateral membrane of the proximal tubule lumen. It
induces natriuresis, kaliuresis, phosphaturia and bicarbon-
aturia. This causes a reduction in these ions in the body,
leading to clinical and biochemical improvement in patients
with hyperphosphataemia.10
Our patient improved clinically after starting therapy with
acetazolamide, with reduced pain and cessation of tumour
formation with no tumour recurrence, as had occurred after
the previous surgical excision of the lesion. Phosphorus levels
decreased but did not reach normal levels.
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